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Abstract 
Background: Pre-marketing authorisation estimates of survival are generally restricted to 
those observed directly in randomised controlled trials (RCTs). However, for regulatory and 
Health Technology Assessment (HTA) decision-making a longer time horizon is often 
required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term 
treatment effect. Registry data can provide evidence to support extrapolation of treatment 
effects from RCTs, which are considered the main sources of evidence of effect for new drug 
applications. A number of methods are available to extrapolate survival data, such as 
Exponential, Weibull, Gompertz, log-logistic or log-normal parametric models. The different 
methods have varying functional forms and can result in different survival estimates.  
Methods: The aim of this paper was to use registry data to supplement the relatively short 
term RCT data to obtain long term estimates of effect. No formal hypotheses were tested. We 
explore the above parametric regression models as well as a nonparametric regression model 
based on local linear (parametric) regression. We also explore a Bayesian model constrained 
to the long-term estimate of survival reported in literature, a Bayesian power prior approach 
on the variability observed from published literature, and a Bayesian Model Averaging 
(BMA) approach. The methods were applied to extrapolate overall survival of a RCT in 
metastatic melanoma.  
Results: The results showed that the BMA approach was able to fit the RCT data well, with 
the lowest variability of the area under the curve up to 72 months with or without the 
SEER-Medicare registry.  
Conclusion: the BMA approach is a viable approach to extrapolate overall survival in the 
absence of long-term data.  
 
 
 
 
  
  
1 Introduction  
Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in 
randomised controlled trials (RCTs). For health technology assessment (HTA) it is important to assess 
the relative effectiveness of products for a longer period of time than is usually assessed in 
conventional RCTs. Extrapolation is a common approach in survival analysis to assess the probability 
of long-term survival following an intervention. Registry data can provide evidence to support 
extrapolation of treatment effects from RCTs, the main sources of evidence of effect for new drug 
applications, because registries generally contain patient cohorts with longer follow-up time than is 
feasible to obtain from RCTs and therefore they could contribute to obtaining better long term survival 
estimates. However, there is no clear recommendation on how to use RCT data in conjunction with 
different types of registry data (individual patient data (IPD) or summary data) for extrapolation 
purposes. There is also uncertainty regarding the best model to use for extrapolation.  
1.1 Previous work and limitations 
Various parametric models have been studied to extrapolate overall survival (OS) from RCTs. One of 
the most commonly used methods to extrapolate the results of RCTs is fitting a parametric survival 
model to the available RCT data, and use the parametric survival model to extrapolate beyond the 
follow-up time of the RCT (Latimer, 2013). The most commonly used parametric survival models 
include the exponential, Weibull, Gompertz, log-logistic and log-Normal regression models (Jackson et 
al. 2016).  
Latimer (2013) evaluated survival analysis methods commonly used for economic evaluations, in 
particular those used for extrapolation when IPD are available. In the review by Latimer (2013), the 
survival analyses used for the technology appraisals conducted by the National Institute for Health and 
Care Excellence (NICE) were evaluated to demonstrate the limitations of survival analyses submitted 
for HTAs. The limitations include the lack of justification of the chosen survival models and the 
limited range of models considered. The issue with the models used for extrapolation is that different 
parametric models have different properties and as such, may yield different estimates of long-term 
survival. To aid the selection of the best model for systematic and transparent extrapolation of survival 
data, a criterion-based approach was provided by Tremblay et al. (2015). Five criteria were provided to 
evaluate a number of techniques used to extrapolate OS and progression free survival (PFS):  
(i) Test the proportional hazard assumption, followed by evaluating criterion (ii) to (v) to select 
the best model 
(ii) Fit extrapolated hazard function, including visual inspection of the extrapolation. Prioritise 
models where the hazard patterns seem reasonable 
(iii) Select parametric model with lowest Akaike Information Criterion (AIC) and Bayesian 
Information Criterion (BIC) to demonstrate goodness-of-fit in the period before extrapolation 
(iv) Account for uncertainty when selecting the best model since high uncertainty would be 
indicative of poor robustness 
(v) Compare the pre and post extrapolation Area Under the Curve (AUC). A rule-of-thumb was 
used: check that the incremental average survival per month does not exceed the value pre-
extrapolation.  
In the example case study in metastatic breast cancer, discussed in Tremblay et al. (2015), the 
Accelerated Failure Time parametric model assuming a Gamma distribution and including a treatment 
covariate was the best of the models used for extrapolation of OS. For PFS, the Kaplan-Meier (KM) 
approach performed better. Limitations of the proposed criterion for selection include the step wise 
approach itself, to first test the proportional hazards assumption. Expert input regarding the underlying 
assumptions from past studies/data may be sufficient to guide which models to use since the statistical 
test may provide conflicting results of what is known from the data. It could therefore be argued that 
  
these steps need not be followed in chronical order. Expert knowledge based on past experience could 
lead to the a priori exclusion of some classes of models. On the other hand, viable models may be 
ignored because the results of the statistical test indicated a false negative result for those models. 
In a recent publication by Guyot et al. (2016) on the extrapolation of survival curves from cancer trials, 
the Surveillance, Epidemiology and End Results (SEER) database (control arm only) was combined 
with other external information to extrapolate survival of RCTs using a single model for all data. The 
standard parametric models were applied with and without the use of the external data. A flexible 
spline model was also applied because the parametric models were unable to fit both the RCT data and 
the SEER data. Limitations of the proposed method include the subjectivity of the opinion regarding 
the long-term effect and the technical difficulty in using spline models when the available data are 
sparse. However, this is not specific to the proposed method. The authors confirm that the use of 
external data could contribute to obtaining “better” (or more appropriate) survival estimates. 
1.2 Aim 
We aimed to combine IPD from a RCT (Robert et al. 2011) with IPD from real world data and with 
summary data from published real world cohort studies (Joosse et al. 2011) to extrapolate the results 
from the RCT. We followed the systematic approach as outlined in the five criteria advocated by 
Tremblay et al. (2015). The ideas are similar to those from Guyot (2016), but we included IPD as well 
as summary data from registries both with and without the corresponding regression models being 
constrained by the external data. Different methods were considered to extrapolate overall survival 
(OS) from the RCT. The commonly used parametric models were applied to extrapolate the OS results 
as well as a nonparametric model based on local linear regression (Li and Racine, 2004). We also 
conducted a Bayesian power prior analysis. Chen and Ibrahim (2006) showed the advantage of the 
power prior approach to estimate the power parameter (variance) especially when multiple historical 
datasets are available. Ibrahim et al. (2015) described the advantages of using power prior approach 
over other informative prior distributions in general linear models, survival models and random effect 
models. Finally, we also considered a Bayesian Model Averaging (BMA) approach. An advantage of 
the BMA approach is that it accounts for both parameter and model uncertainty (Hoeting et al., 1999). 
The SEER database linked with Medicare claims data was used to obtain relevant treatment 
information needed for extrapolation of the RCT data. 
 
The manuscript is constructed as follows: in the methods section the example data are described as well 
as the models used for extrapolation. This section also describes the different techniques, in particular, 
the so-called non-informative extrapolation, extrapolation using combined sources of evidence and 
extrapolation using registry data. A constraint regression analysis and a BMA approach are also 
described. The results for each approach are described in similar order in the results section as they 
appear in the methods section. The methods were applied to extrapolate the results of an RCT in 
metastatic melanoma. In the discussion section further discussion is provided on the use of real world 
data (RWD) for extrapolation of overall survival. It should be explicitly noted that extrapolation was 
applied on the overall survival results of the individual treatments separately. Also, due to the 
availability of registry data for standard of care (SOC) only, the constrained regression and Bayesian 
power model approach were applied on the SOC arm only. 
2 Methods 
The commonly used parametric models for extrapolation of RCT results are applied to extrapolate the 
OS results. To provide an alternative to parametric extrapolation, a nonparametric alternative based on 
local linear regression (Li and Racine, 2004) is also used.  
A Bayesian power prior approach and Bayesian Model Averaging approach are also presented as 
alternatives. The following section provides a more detailed description of the data available and the 
methods applied. 
  
2.1 Available data used to illustrate methods 
Randomised controlled trial data 
IPD were obtained from an RCT in untreated patients with metastatic melanoma (Robert et al., 2011). 
Patients received SOC or an experimental treatment. A total of 502 patients were randomised in a 1:1 
active to placebo ratio. Patients were followed up for 48 Months. Figure 1 illustrates the survival 
probabilities for each of the treatment arms included in the trial. 
 
 
Figure 1 Survival probability for the experimental treatment and standard of care 
 
Data from literature 
A literature search was performed to identify studies that included patients with metastatic melanoma 
similar to those included in the RCT. Two studies were identified that included results useful for 
purpose of the extrapolations: 
Joosse et al (2011) published long-term estimates of survival of patients from the Munich cancer 
registry. A total of 11,774 patients were selected from this registry, which includes patients who were 
diagnosed with cutaneous melanoma. The study reported 1321 events (11.9%) of lymph node 
metastasis and 1602 events (13.7%) of distant metastasis. Total follow-up time was 120 months and 
median follow-up time was 80 months.  
The published long-term survival estimates from Joosse et al. (2011) were used to assess the 
plausibility of the extrapolation strategies through visual inspection of the extrapolated results and are 
presented in Figures 3a, 3b, 5, 6 and 7 for reference purposes only. The lower of the two tick marks, in 
the figures mentioned above, at 80 months represents the survival probability of lymph node 
metastasis. The higher tick mark at 80 months (displayed at 81 months for clarity) represents the 
survival probability for distant metastasis.  
In Altomonte et al. (2013) data were collected from metastatic melanoma (stage III/IV) patients who 
failed or did not tolerate previous treatment for metastatic melanoma in Italy and were enrolled in an 
expanded access program for the experimental treatment in the RCT. The published results included 
KM curves of patients followed up for 48 months. The KM curves were used to reconstruct IPD using 
the approach proposed by Guyot et al. (2012). As a result, these IPD could be combined with IPD data 
from the RCT to extrapolate long-term survival.  
  
SEER-Medicare cohort 
The SEER registry linked with Medicare claims (SEER-Medicare database) was used to obtain relevant 
treatment information needed for extrapolation of the RCT data. The SEER-Medicare database is the 
linkage of two large US population-based data sources that provide patient-level information on 
Medicare beneficiaries with cancer. A real world cohort of elderly patients (>66 years of age) with 
treated primary metastatic melanoma, reflecting the target patient population of the trial (by applying 
the same inclusion/exclusion criteria as in the studies), was created from the SEER-Medicare database. 
The inclusion and exclusion criteria of the RCT, for which it was desired to extrapolate the survival 
estimates were applied to the SEER-Medicare database to extract a cohort of patients that reflect the 
RCT target patient population. Metastatic melanoma patients were identified according to the 
International Classification of Disease for Oncology (ICD-O-3: 8720/3 or 8720/2) and concurrent 
topology codes (C44.x). Treatment was identified in the Medicare database with line of treatment 
defined through a stepwise algorithm (Zhao et al., 2014). All patients included in the cohort had 
continuous enrolment in Medicare (patients enrolled in a health maintenance organization (HMO) or 
hospice in a certain time window were excluded) to allow for sufficient and continuous follow-up of 
the study period. See also the supplementary material for further information on the extraction of data 
from SEER-Medicare, which is provided in the appendix. There were 47 patients on SOC and 84 
patients on experimental treatment. At approximately 80 months 46 (98%) of those treated with SOC 
and 48 (57%) of those treated with experimental treatment had died. In Figure 2, the survival 
probabilities for the experimental treatment and SOC obtained from the SEER-Medicare database are 
presented. 
 
 
Figure 2 Survival probability for the experimental and standard of care – SEER-Medicare data 
 
2.2 Statistical models 
Parametric models 
As mentioned in the introduction, for purpose of this work, the most commonly used parametric 
models for the analysis of survival data were used to illustrate the extrapolation strategies. In particular, 
the Weibull, Gompertz and Exponential as well as the lognormal and log-logistic models were applied 
to the RCT data. For further details and examples of these parametric survival models we refer to 
Rodriguez (2005). 
Let T be a random variable denoting the survival time then S(t)=P{T>t} is the probability of being 
alive at time t. In the case of the lognormal model we define  as the cumulative standard normal 
distribution and Log(T) is normally distributed with mean µ and variance 2 (N(µ, 2)). Table 1 
presents the functional forms of the parametric models investigated. 
 
  
Table 1 Main parametric survival functions (S(t)) applied and their hazard functions 
(h(t)) 
Model  (S(t))   h(t)    
Exponential  exp(-t)    
Weibull  exp(-(t)p)   p(t)p-1 
Lognormal  1-[(log(t)-µ)/]  ((Exp[-1/2((log(t)-µ)/ )])/t(2)1/2))/S(t) 
Log-logistic  1/(1+(t)p)  ptp-1p/(1+(t)p) 
Gompertz  exp((1-exp(pt))  exp(pt) 
 
The parameters  (scale parameter), p (shape parameter), µ and  are estimated from the data. In the 
case of the Weibull function, if p>1 this denotes an increasing hazard, while p<1 denotes decreasing 
hazard. When p=1 the Weibull model reduces to an exponential model, and as such it can be 
considered a more general version of the exponential model. The Gompertz model assumes that the 
survival decreases over time at an exponential rate. As is the case with the Weibull function, p<1 and 
p>1 correspond with decreasing and increasing hazard and when p=1 the model reduces to an 
exponential model. 
In situations where the distribution of the survival times is skewed and the variability is uncertain, or 
high, the lognormal distribution may be an appropriate model to use. For such a model the logarithm of 
the residual errors is assumed to come from a normal distribution. 
It is assumed that the assumptions underlying a survival analysis are inherited from the RCT data and 
still hold due to the independently selected additional data (SEER-Medicare data and long term 
summary measures reported in literature). In particular, it is assumed that the proportional hazards 
assumption is met, i.e. the ratio of the hazards between two individuals is constant over time, the 
observations are independent (by design) and the linear relationship between the covariates and 
survival is linear. 
Sponsors do not routinely use nonparametric models for extrapolation of RCT data as was seen in 
Latimer (2013). As a result, a nonparametric model was also used to illustrate how such a model could 
be used. In contrast to parametric modelling a nonparametric model does not assume a specific 
distribution for the data. In particular, a local linear model was chosen as it is very flexible and can 
accommodate any number of empirical distributions, which may be of particular interest in the tail of 
the RCT where there is great uncertainty due to the presence of censored data. The following section 
describes the nonparametric model in more detail. 
Nonparametric model 
In addition to the applied parametric models, we applied a so called non-parametric model based on 
local linear regression. This model is referred to as nonparametric because it does not a priori assume a 
shape of the response curve (Li and Racine, 2004). This model was selected because it is relatively 
easy to understand and is based on a basic mathematical principle that any function can be estimated by 
a series of local linear functions, e.g. Newton’s method for estimate the extreme values on a curve 
(Clapham and Nicholson, 2014). 
In summary, assuming we need to estimate an unknown function f(t) in the interval [a,b]. The interval 
[a,b] can be split in finite intervals starting from [a,xi]….[xn,b] of chosen bandwidth. The bandwidth of 
each interval can be arbitrarily chosen. However, the accuracy of the estimation will depend on the size 
of the chosen bandwidth, i.e. the smaller the bandwidth the more accurate the prediction but more 
accurate prediction requires more iterations. If the bandwith is chosen such that the length is equal to 
the distance between two subsequent data points then the model will connect the data points. The 
estimate of the function in the time interval [a,xi], )( ],[ ixatf

, is a linear model with slope [s(a)-s(xi)/|a-xi| 
for a decreasing function. Here s(x) denotes the response value at (time) x. 
  
In general, assuming that S(t) is the survival time at time t, the model as proposed by Li and Racine 
(2004) is as follows: 
))(()( txgtS =  
where g(x(t)) is a local linear fit applied to a range of data points in time and estimated directly from 
the data observed and x(t) is the vector of regressors, e.g.time. 
Models were fitted in R (R core team, 2014) and WinBUGS (Spiegelhalter et al., 2003). Goodness of 
fit for the parametric models was evaluated through assessment of the log likelihood test statistic or the 
Deviance Information Criterion (DIC) in WinBUGS. The log likelihood for the nonparametric model 
was calculated using the conditional density. A lower value indicates a better fit. The models were 
additionally assessed through visual inspection. 
The following sections outline how these models were applied to the example data. 
2.3 Non-informative extrapolation 
The parametric statistical models described above and the non-parametric model were fit to available 
RCT data by regression analyses. The regression model was extended from 48 months (the length of 
follow-up in the RCT) to 80 months, assuming no data were available from 48 months to 80 months. 
The case when there are no long-term follow up data available, will be referred to as non-informative 
extrapolation. 
2.4 Extrapolation using re-created IPD from published KM curve and long-term 
follow-up study as reference 
Individual patient data and OS probabilities were recreated from published KM curves (Altomonte, 
2013) using the DigitizeIt software (http://www.digitizeit.de/) and R (R core team, 2014) 
code from Guyot et al. (2012). Guyot et al. (2012) described an algorithm for digitizing published KM 
curves back to KM data by inverting the KM equations, using the number of events and numbers at risk 
(if available). They compared their reproduced survival probabilities, including median survival times 
and hazard ratios with the published results. It was shown that the reproduced results were comparable 
to the original results. However, accuracy of the reproduced results was reasonable only if at least the 
number of patients at risk or the total number of events were reported in addition to the KM curves.  
In Altomonte (2013) the KM curves as well as the number of patients at risk were reported. As a result, 
we were able to apply the methodology described by Guyot et al. (2012) to the Altomonte published 
results and generate survival probabilities from the Altomonte published results to use in our attempt to 
extrapolate the results from the RCT. 
Long-term survival results published from a large registry study (Joosse et al., 2011) was used to assess 
the plausibility of the extrapolation. This was done through visual inspection. Visual inspection was 
also performed in the approaches described in Sections 2.5, 2.7 and 2.8. For the constrained regression 
analyses (Section 2.6) the long term survival was used to constrain the applied models. 
In the remainder of this document the long-term survival results from the registry study (Joosse et al., 
2011) is referred to as “LT follow-up study”. Only the best fit parametric models from the non-
informative extrapolation, i.e. log-logistic and lognormal models and the non-parametric model are 
presented to illustrate this and the following approaches. 
2.5 Extrapolation using SEER-Medicare data and LT follow-up study as reference 
Data from the SEER-Medicare database were used to extrapolate the results from the RCT, based on 
the selected parametric and non-parametric survival models. IPD were generated from the life-table 
estimates (which included the survival probability, time (months), number of patients at risk and 
number of patients censored) obtained from the SEER-Medicare patient cohorts using a minor 
  
modification of the code provided by Guyot et al (2012). The results from the period to be extrapolated 
were merged (blended) with the RCT data by adding the SEER-Medicare data to the RCT data to 
create one dataset. This dataset was then used for extrapolation using the models described in 
Section 2.2. The available follow-up time from the SEER-Medicare data was less than 80 months for 
SOC and about 110 months for experimental treatment. Using this follow-up time in the extrapolation 
range may reduce the uncertainty around the estimates obtained from the extrapolation. As a result, the 
extrapolations have been carried out with and without the SEER-Medicare data to investigate the 
impact of including these data in the extrapolation strategy.  
Because of the uncertainty of the RCT data at the end of the follow-up period due to censoring, the last 
10%, 20% or 30% of the RCT data at the end of the follow-up period was removed. The analyses 
presented here excluded 10% of the RCT data at the end of the follow-up period. Removing more data 
resulted in a poor statistical fit and is not recommended (Zwiener et al., 2011).  
The most commonly reported period for assessment of long-term survival (Queiroga et al., 2003; Kelly 
and Halabi, 2010) is around 5 to 6 years (72 months). To provide an estimate of long-term overall 
survival the area under the survival curve restricted to 72 months of follow-up was estimated, i.e. 
AUC0-72, together with its standard error. A restricted AUC measure is often used in Health Technology 
Assessment (HTA) groups to establish the long-term survival associated with a treatment (Tappenden 
et al., 2006). 
Note that for illustrative purposes, and due to the availability of data, the approach using the SEER-
Medicare data is demonstrated with the control arm of the RCT only. However, the methodological 
principles apply to any treatment arm in an RCT, subject to the comparability of patients in both the 
RCT and RWD cohort. 
2.6 Extrapolation using SEER-Medicare data and Bayesian power model 
constrained to the long-term follow-up study 
Let 0 be the weight of the historical data relative to the current study (0≤0≤1), and L(|D) the general 
likelihood function for a regression model with parameter vector , given data D of the current study. 
Let 0() be the prior distribution for theta before the historical data Do is observed. Then the power 
prior distribution of  (for the current study) is defined as (Chen and Ibrahim, 2006): 
)()|(),|( 0000
0  DLD   
Chen and Ibrahim (2006) demonstrated the advantage of a power prior approach especially when 
multiple historical datasets are available to estimate the power parameter. Ibrahim et al. (2015) describe 
the advantages of using power prior approach over other informative priors in general linear models, 
survival models and random effect models. The advantages described include: 
(i) The techniques to show adequacy of (|D0, 0) are the same as those for showing adequacy 
of the posterior distribution with likelihood function L(|D) and prior 0(), using likelihood 
theory 
(ii) Variable selection and general model selection problems can be investigated using varying 
(power) prior distributions 
(iii) The asymptotic properties resulting from the likelihood theory also hold for the power prior, 
since the power prior is a likelihood raised to a power (0) 
The rest of this section describes how the Bayesian power prior model was constrained using the long-
term follow-up study information in order to estimate long-term survival.  
Let S(ti) be the survival time at time ti and S(tobs) is the observed survival time at time tobs from the 
long-term follow-up study. The median survival time observed from the long-term follow-up study was 
  
80 months. Let also, 
2
obs  denote the observed variance from the long-term follow-up study. Then the 
lognormal constraint model (Guyot et al., 2014) is: 
72,..,1],/))[(log(1)( =−−= ittS ii   
Subject to the constraint 
obsobs StS =)(  
Similarly, the Log-logistic constraint model is: 
72,..,1),)(1/(1)( =+= ittS ii
  
and ensuring the survival function is constrained to the observed long-term time and survival 
obsobs StS =)(  
For varying levels of α, the precision of the estimates of survivals were defined as follows (assuming 
τ=1/σ for the log-logistic model):  
( ) 2* /1][ obsjtS =  
In practice, the choice of the level of α will depend on the confidence and acceptability of the 
(precision of) real world summary data. For this example, we allowed α to range from 0.001 (low 
precision) to 1. As a sensitivity analysis α was also set at 2 (higher precision). The scenario where α =1 
coincides with the observed variability from the published long-term registry study, i.e. accepting it at 
“face value”. 
The prior distributions for μ and τ were assumed to be a normal (N(0,0.01)) and a gamma distribution 
((0.001,0.001)) respectively. 
The Bayesian power model was applied with (SOC only) and without the SEER-Medicare registry data 
to illustrate the impact of the RWD and the applied methodology. The long term lymph node metastasis 
survival result by Joosse et al. (2011) was used to constrain the regression models (see also Sections 
2.1 and 2.4). 
2.7 Extrapolation using SEER-Medicare data and BMA 
An advantage of the Bayesian Model Averaging approach is that it accounts for model uncertainty 
(Hoeting et al., 1999). For the two best fitting survival models the lognormal and logistic, a BMA 
approach (Jackson et al., 2009) was applied. Let SLN(t) denotes Lognormal survival function and let 
SLL(t) denote the log-logistic survival function. Determine weights W1 and W2 such that the overall 
survival function is the weighted average of the individual components: 
)()()( 21 tSWtSWtS LLLN +=  
With Wi being the weighted average of the Deviance Information Criterion (DIC) obtained from each 
individual (SLN or SLL) model fit. 
This approach can be extended to incorporate other plausible survival models as appropriate. 
  
2.8 Sensitivity analyses of chosen weights in the BMA approach 
To investigate the acceptability of the weights, sensitivity analyses were performed using different 
weight options obtained from fitting the models in WinBUGS. In the first option, the Weights were 
estimated as the weighted average of the restricted Area under the curve up to 72 months, AUC0-72, 
obtained from the individual model fit.  
A weighted average of the estimated location parameter (μ) from each survival function were also used 
as weights. Based on the asymptotic properties of the log-logistic and lognormal distributions (Dey and 
Kundu, 2010) such an approach appears to be valid for large sample sizes. Dey and Kundu also 
provided correction factors for estimating the probability for correct selection of each model in cases 
when the sample size is smaller. These correction factors were not further investigated in the context of 
this research 
As described in Section 2.2 and 2.5, AUC0-72, together with its standard error was used to describe long 
term survival. A model with a lower Deviance Information Criteria (DIC) as estimated by WinBUGS 
(Spiegelhalter et al., 2003) was considered a better model. 
3 Results 
3.1 Non-informative extrapolation 
The 5 parametric models seem to fit the data reasonably well. The log-likelihood test statistic was 
lowest for the lognormal and log-logistic models indicating a better fit. Table 2 presents the results of 
the log-likelihood test statistic for the selected models. 
 
Table 2 Model fit results for selected models applied to the RCT data. 
Model -2xloglikelihood (-2LL) 
Exponential  3120.7 
Weibull  3119.8 
Lognormal  3068.0 
Log-logistic  3067.2 
nonparametric 2100.8 
 
The results of the extrapolation for the lognormal and log-logistic models in the absence of long term 
follow-up data are presented in Figure 3a. The plausibility of the extrapolated survival curve beyond 
the RCT data is uncertain, especially when benchmarked against the results of the long-term registry 
study (Joosse et al., 2011). The estimate (SE) for the restricted AUC from 0 to 72 months for SOC was 
15.7 (1.2) for the best fitting log-logistic regression model. 
 
  
 
Figure 3a Left panel: Non-informative lognormal extrapolation of RCT data. Right panel: Non-informative log-
logistic extrapolation of RCT data 
 
With regards to the nonparametric regression model, it was observed that this model fits the RCT data 
extremely well as confirmed by the smallest log-likelihood of all the models. However, due to the lack 
of follow-up data and the number of censored observations in the tail of the observed RCT data, the 
extrapolation using this model when there is no follow up data is inaccurate. If follow-up data and 
external data are available in a reasonable number of time intervals the nonparametric model would be 
a good alternative to use for extrapolation. However, if data are sparse the nonparametric model may 
not be appropriate. As a result, this model was not taken further in the subsequent evaluations but was 
presented here for illustrative purposes. Figure 3b is presented as an illustrative example of what can be 
expected if this model was to be used in a constraint extrapolation with sparse data. The long term 
study (Joosse et al. 2013) is the only available data for the period to be extrapolated and the survival 
probability is at a much later time point (80 months) than the follow-up period of the RCT (48 months). 
As a result, the linearity as imposed by the nonparametric extrapolation in the extrapolated interval, is 
questionable. 
 
 
Figure 3b Nonparametric extrapolation of RCT study data including published RWD from long-term study 
(Joosse et al. (2011)) 
 
  
Non-informative extrapolation may be useful when there is real world data available in a reasonable 
interval in the extrapolation range and the model fit the RCT data reasonably well. However, 
extrapolation is unreliable in the absence of long-term data. Due to censoring, the follow-up data of the 
RCT are also uncertain which may have an impact on the quality of the extrapolation. In line with the 
recommendations from Latimer (2013), 10% of the follow-up data was removed prior to extrapolation 
in the remainder of the paper. 
3.2 Extrapolation using re-created IPD from published KM curve and long-term 
follow-up study as reference 
The recreated IPD from published KM-curve and the resulting KM curve are presented in Figure 4. 
 
 
Figure 4 Digitised Kaplan-Meyer curve of real-world study (Altomonte (2013)) 
 
The published results (Altomonte, 2013) approximated those from the patients receiving SOC. 
However, the follow-up time reported in the published study was similar (even shorter) to the RCT 
follow-up (48 months). Therefore, the re-created IPD from the KM curve would not be useful for 
extrapolation purposes and, in this case, digitizing the published Kaplan-Meier curve did not result in 
useful data for extrapolation. This approach is presented here as an option to obtain external data for 
extrapolation and could be useful in case the follow-up time of the published KM estimates are longer 
than the follow-up time of the RCT.  
3.3 Extrapolation using SEER-Medicare data and long-term follow-up study as 
reference 
Blending of RWD (SEER-Medicare data) with RCT data (by adding the estimated RWD survival 
probabilities from the extrapolation interval to the survival probability data from the RCT) resulted in a 
reduction in the uncertainty of the long-term survival estimate (AUC0-72) compared to the non-
informative extrapolation. The estimate (SE) was 14.8 (1.1). However, this reduction in the standard 
error should be interpreted with caution and should be considered in conjunction with the 
appropriateness of the RWD. Based on the long-term summary results (Joosse et al. 2011) and the data 
obtained from the SEER-Medicare registry, clear judgement is needed regarding the acceptability of 
RWD. For example, the SEER-Medicare registry provided long-term data useful for extrapolation of 
the SOC arm. However, the early follow-up period (up to 48 months) would appear to differ from the 
RCT data as is illustrated in Figure 5. Moreover, the extrapolation results of the SOC arm does not 
  
approximate the results from Joosse et al. (2011), which showed superior survival probabilities at 80 
months, compared to the probable time course of the RCT extrapolation. 
 
 
Figure 5 Extrapolation of RCT data using SEER-Medicare data 
 
3.4 Extrapolation with and without SEER-Medicare data and Bayesian power 
model with constraint on the long-term follow-up study 
Without SEER-Medicare: 
The AUC0-72 (SE) using the lognormal model to model the survival of patients on SOC arm was 17.8 
(1.1), 17.0 (1.0) and 17.0 (0.9) for α=0.2, α=1.5 and α=2, respectively. This illustrates a further 
reduction in the uncertainty in the long-term survival estimate compared to the previous approach. 
Figure 6 illustrates the model fit for varying levels of alpha (left graph) and for the best fitting levels of 
α (right graph) for both treatment arms. Constraining the model to the summary RWD (Joosse et al, 
2011) results in the extrapolation curve departing slightly from the RCT portion of the data, as the 
extrapolation model aims to approximate the summary RWD.  This could be indicative of what was 
observed previously, that the 80 month survival probabilities of the published RWD (Joosse et al. 
2011) are superior to the possible long term survival probabilities of the SOC arm.  
 
  
  
Figure 6 Extrapolation of SOC with the Bayesian power prior approach without SEER-Medicare data for all levels 
of the power component (left panel) and selected levels of the power component (right panel) 
 
For the patients receiving experimental treatment, the AUC0-72 (SE) for α=0.001, α=0.5, α=0.6, α=1/2 
was 20.9 (1.2), 20.8 (1.2), 20.7 (1.1) and 20.3 (1.1), respectively. Figure 7 illustrates the results of the 
Bayesian power prior approach with constraint for the experimental treatment arm and illustrates how 
well the methodology worked when the long-term registry results (Summary RWD from the long-term 
registry study (Joosse et al., 2011)) is an achievable target to extrapolate towards. 
 
  
Figure 7 Extrapolation of Experimental treatment with the Bayesian power prior approach without SEER-
Medicare data for all levels of the power component (left panel) and selected levels of the power component (right 
panel) 
 
With SEER-Medicare (SOC only): 
The AUC0-72 (SE) were 18.1 (1.2), 17.3 (1.0) and 17.3 (1.0) for α=0.2, α=1.5 and α=2, respectively. 
The results indicate that as the precision in the RWD (Joosse et al., 2011) decreases (i.e. an increase in 
the variability of the long-term RWD estimate) the RCT data are better fit with a marginal worsening 
of the uncertainty in the long-term survival estimate compared to when the registry data was not used. 
However, using the registry data resulted in lower variability in AUC0-72 compared to the non-
informative extrapolation case. 
The results were similar for the log-logistic case, with the results for the log-logistic case being 
marginally better than those for the lognormal case. 
For this approach, the reliability of the results of the extrapolation is dependable on the acceptability of 
the estimate and variation of the available long-term RWD (Joosse et al., 2011). Whether or not the OS 
  
result of the RCT when extrapolated can realistically approximate the long-term estimate is also a point 
to consider. 
3.5 Extrapolation using SEER-Medicare data and BMA 
The Bayesian model averaging approach reduced the uncertainty of the long-term survival estimate the 
most compared to all the previous methods, with or without the use of the SEER-Medicare registry 
data. Without the use of the registry, the AUC0-72 (SE) for SOC was 15.1 (0.76) and for patients on 
experimental treatment the AUC0-72 (SE) was 20.9 (0.97). The log-likelihood statistic (-2LL) was 
3306.7 and 1627.8 for the lognormal and log-logistic model respectively. These estimates were also 
lower than those from previous models, indicating improved fit with reduced uncertainty. 
When the registry data are blended (see Section 2.5) with the RCT data (SOC only), the AUC0-72 was 
15.8 with a marginally larger increase in uncertainty (0.78). This estimate is still lower than the 
previous methods, indicating superiority of the BMA approach compared to the previous methods, at 
least in terms of uncertainty. The likelihood ratio test statistic was 3341.6 and 1646.4 for the lognormal 
and log-logistic model respectively. These were marginally larger than without the SEER-Medicare 
data but still lower than those observed before. However, contrary to what was observed in the power 
prior approach, the BMA approach fit the RCT data reasonably well and the extrapolated results seem 
to approximate the results published in Joosse et al. (2011), especially for the experimental arm.  
 
Table 3 provides a summary of the results of AUC0-72 for SOC with and without registry data for the 
lognormal model. 
 
Table 3 Summary of results of AUC0-72 (SE) for SOC with and without registry data for the 
lognormal model. 
Method        AUC0-72 (SE) 
Non-informative extrapolation     15.7 (1.2) 
Extrapolation using registry data and long-term follow-up study 14.8 (1.1) 
Bayesian power model without SEER-Medicare (α=2)  17.0 (0.9) 
Bayesian power model with SEER-Medicare (α=2)   17.3 (1.0) 
Bayesian model averaging without SEER-Medicare   15.1 (0.76) 
Bayesian model averaging with SEER-Medicare   15.8 (0.78) 
 
Future work in this area could include a combined BMA and Bayesian power prior approach to 
investigate whether combining these approaches will improve the extrapolation results compared to the 
BMA and Bayesian power prior approach individually. 
3.6 Sensitivity analyses of chosen weights in the BMA approach 
When the weighted average of the restricted Area under the curve up to 72 months were used as the 
weights in the BMA approach, the estimate for long-term survival was 16.8 (0.86) for SOC and 21.7 
(1.01) for patients receiving experimental treatment. In the case that μ of the individual model fits were 
used as weights, the AUC0-72 (SE) was 16.7 (0.88) for SOC and 21.9 (1.05) for patients receiving 
experimental treatment.  
The results presented here are for the case including the SEER-Medicare registry. These results 
confirm that the BMA approach was able to reduce the uncertainty of the extrapolation of overall 
survival compared to the other approaches presented.  
 
4 Discussion 
We considered different approaches that could be used to extrapolate results of RCTs to estimate long-
term survival, with or without external data. In the absence of long-term follow-up data, non-
informative extrapolation may be considered. However, due to loss to follow-up, the fit in the tail of the 
  
RCT follow-up may be inadequate. This was most visible in the non-parametric model, which fit the 
RCT data particularly well, as confirmed by the smallest log-likelihood statistic, but nevertheless 
showed a poor fit in the tail of the follow-up period. If a reasonable amount of external data were to be 
available in the period to be extrapolated then the nonparametric model could be a good alternative to 
the parametric approaches. A model that can be used for extrapolation should fit both the RCT data as 
well as the external data collectively. However, as proposed by Tremblay (2015) the first step is to 
ensure the model fits the RCT data well. 
The use of SEER-Medicare registry data allowed for extrapolation of RCT results to establish long-
term survival with reduced uncertainty. The overall survival results of the IPD which were obtained by 
digitizing published KM curves of RWD cohorts (Altomonte, 2013) were consistent with findings from 
the RCT. However, the follow-up of patients in this data source was similar to those in the RCT so did 
not allow for long-term extrapolation. By combining the RCT with the SEER-Medicare cohort and 
using the long-term registry study as a reference the long-term extrapolation was achieved, the 
uncertainty was reduced and the plausibility of the extrapolation was benchmarked. The magnitude of 
the reduced uncertainty could be driven by the relatively long follow-up of this example RCT and the 
uncertainty could potentially be larger when extrapolating trials with shorter follow-up. 
As mentioned earlier, for purpose of this work, the most commonly used parametric models for the 
analysis of survival data were applied to illustrate the extrapolation strategies: the Weibull, 
Exponential, log-logistic and lognormal. However, other parametric models such as the Gamma, 
Gompertz, Generalised Gamma or Generalised F could also be considered. The applied nonparametric 
model was chosen due to its flexibility and computational simplicity. However, other spline models or 
fractional polynomials could also be applied (Royston & Lambert, 2011). 
The BMA approach was superior to the other approaches investigated: it reduced the uncertainty in the 
long-term estimate of survival with a reasonable fit to the RCT data as indicated by the log-likelihood 
test statistic. The reduction of uncertainty should be considered in conjunction with the model fit 
diagnostics and the appropriateness of the external data. In this case study the patients from registry 
were selected to reflect the RCT population as closely as possible. With respect to the models used, we 
included only those parametric models that best fit the RCT data. Another approach would be to fit all 
parametric models considered. However, the models that do not fit the RCT well will have potential to 
add noise to the BMA approach. The inclusion of all models has greater value for reducing noise when 
models are adequate but none is better than the other. BMA may reduce the uncertainty from all the 
individual models. However, Fragoso and Neto (2015) performed a systematic review of the use of 
BMA in various areas of research and concluded that little consideration has been given as to how to 
select which models to include in BMA. Further research to evaluate selecting the best models 
compared with including all models in the BMA approach is warranted to provide guidance or 
recommendations in the future.  
The extrapolation analyses presented here excluded 10% of the RCT data at the end of the follow-up 
period to remove some of the uncertainty in the tail of the survival distribution due to patients being 
censored. As part of a sensitivity analysis more data (e.g. 20% or 30% of the RCT data at the end of the 
follow-up period) were also removed, but this resulted in poor fit to the RCT data, and was therefore 
not pursued or considered appropriate in this case study. This is consistent with the recommendations 
by Zwiener et al. (2011). A simulation study to evaluate different data cut-offs of the RCTs as well as 
the registry data could be considered for future research. 
A limitation of this analysis was the difficulty to access IPD from multiple registries. When registry 
data are available only summary statistics are sometimes provided. Although summary statistics are 
useful, this can limit the analyses that can be performed using RWD, such as the adjustments for 
patient characteristics that have an impact on their long-term survival, e.g. the Eastern Cooperative 
Oncology Group (ECOG) status at baseline. Additionally, these extrapolations were based on a cohort 
of US elderly patients, whose survival may not be generalizable to younger patients. However, this 
subgroup of patients is considered to represent a key subgroup of metastatic melanoma patients, with 
the median age of metastatic melanoma diagnosis of 63 years (Howlader et al., 2016). As discussed in 
the introduction, previous extrapolation studies have been undertaken with SEER data (Guyot et al., 
2016). SEER provides data on cancer patients of all ages, but systemic anti-cancer treatment 
  
information is limited. Utilizing survival and patient cohorts not segmented by systematic treatment 
regimens may result in biased results as the extrapolations are based on data from two patient cohorts 
treated with treatments of different efficacy or mechanisms of action. Moreover, as was described the 
effects in the SEER-Medicare cohort up to 48 months were different than those observed in the clinical 
trial. One of the reasons for this could be poor adherence to medication or different treatment strategies, 
as these have been reported to be the main reasons for differences in effects in RCTs compared to real 
world data (Carls et al., 2017; Martin et al., 2005). It is unknown whether patient compliance or 
different treatment strategies were the reasons for the difference in effects observed in the RCT and 
SEER-Medicare cohort up to 48 months. This warrants further investigation. 
The use of IPD and summary data to extrapolate and to assess the plausibility of the extrapolation was 
useful in this analysis. The methods that can be applied in practice will depend on which type of data 
are available, e.g. IPD or aggregate data. However, further research is warranted to evaluate different 
approaches with multiple RWD cohorts and assess the impact of using summary data. Additional 
research could include combining Bayesian Model Averaging techniques (Jackson et al. 2009) and 
constrained regression models (Guyot et al. 2014) in combination with the power prior approach on the 
uncertainty, especially using prior model probability weights based on external (real world) evidence 
(Abrams & Happich, 2016). In cases where long term survival is established in a disease area, the 
consistency and reproducibility of the AUC0-72 could also be evaluated through simulations as a way to 
support a claim whether a drug provides evidence of long term survival.  The sensitivity analyses 
confirmed the robustness and adequacy of the Bayesian Model averaging for extrapolation. The 
asymptotic properties of the lognormal and log-logistic distribution allows the use of the location 
parameter as a weighting factor. However, using the location parameter as a weighting factor warrants 
further investigation, particularly in smaller sample sizes. 
Acknowledgements The research leading to these results was conducted as part of the GetReal consortium. 
For further information please refer to www.imi‐getreal.eu. This paper only reflects the personal views of the 
stated authors. The work leading to these results has received support from the Innovative Medicines Initiative 
Joint Undertaking under grant agreement n° 115546, resources of which are composed of financial contribution 
from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind 
contribution. 
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole 
responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of 
Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the 
Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-
Medicare database. 
The authors also express their gratitude to Rachel Kalf and Amr Makady of the National Health Care Institute 
of the Netherlands, Zorg Institute Nederland (ZIN) for performing the literature search to identify relevant 
studies that reported KM curves. 
Conflict of Interest  
The authors Reynaldo Martina, David Jenkins, Pascale Dequen, Michael Lees and Frank Corvino have 
declared no conflict of interest. Keith Abrams has served as a speaker, a consultant and an advisory board 
member for Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-
Ceutical, GSK, Janssen, Merck, Novartis, NovoNordisk, Pfizer, PRMA, and Roche, and has received research 
funding from Pfizer and Sanofi. Sylwia Bujkiewicz has served as a speaker and a consultant for Roche. Jessica 
Davies declares stock ownership and employment with F. Hoffman-La Roche Ltd. 
 
Appendix A Supplemental material relating to the SEER-Medicare cohort 
A.1 Data source 
Observational data from the National Cancer Institute’s (NCI) SEER-Medicare program was used to 
extract a cohort of elderly patients with newly diagnosed metastatic melanoma receiving treatment. 
NCI’s program provides the linkage of two large US population-based data sources that provide 
patient-level information on Medicare beneficiaries with cancer. Briefly, SEER is a United States 
  
national cancer registry covering 28% of the population with the aim of providing tracking on cancer 
incidence and survival. The data provides patient-level information on cancer patients of all ages with 
data on demographics, tumor characteristics (stage, histology, site location), and patient survival. The 
registry is linked to the Medicare insurance claims database, which is a nationally funded health insurer 
in the US, provided to all residents ≥65 years of age or diagnosed with end-stage renal disease or other 
disabilities. 97% of US residents ≥65 years of age qualify for Medicare coverage (National Cancer 
Institute, 2016). 
In this study we used a 2015 SEER-Medicare release database, which included SEER diagnosis and 
death information between January 1, 1995 and December 31, 2012 with Medicare claims through 
December 31, 2013. Part D (outpatient prescription drug) data are available between Jan 1, 2007 and 
Dec 31, 2013 
A.2 Cohort selection 
In this study we included treated elderly patients (≥66 years of age) diagnosed with metastatic 
melanoma between January 1, 2004 and December 31, 2011. We extracted patients with an 
International Classification of Disease for Oncology (ICD-O-3) code 8720/3 or 8720/2 and concurrent 
topology codes (C44.x) (n=7,149). Stage at diagnosis was extracted from the SEER database, and only 
patients with metastatic disease at diagnosis were selected. SEER provides stage information using the 
American Joint Committee on Cancer (AJCC) staging system. Patient selection was cut-off on 
December 31, 2011 to allow for at least one year follow-up after metastatic diagnosis. Patients with a 
diagnosis of a primary tumor other than melanoma 6-months prior or any time after melanoma 
diagnosis were excluded. Additionally, all patients had continuous enrollment in Medicare Part A and 
Part B (no enrollment in a health maintenance organization or hospice) for at least 1 month prior to 
diagnosis and during the entire follow-up period to ensure ability to create health history data for each 
patient. The age cut-off was ≥66 years of age at diagnosis to allow for at least 1 year of Medicare data 
prior to diagnosis. 
All patients included in the cohort initiated front-line treatment with the treatment(s) of interest as a 
monotherapy or combination. This was identified through ≥2 Medicare claims after diagnosis date 
(n=131). 
A.3 Treatment algorithm 
Treatment lines were defined based on previous insurance claims studies in metastatic melanoma 
(Zhao, 2014). First-line treatment was defined as receipt of first systemic anti-cancer treatment 
consisting of the treatment(s) of interest as monotherapy or combination initiated any time after 
metastatic diagnosis. At least two claims of the particular agent had to occur within 28 days to be 
considered. Combination therapies were defined as occurrence of both therapies within the same 28 
day window. A new line of therapy was defined as either a 90-day gap in treatment or initiation of a 
new regimen that does not occur within 28 days of the start of the previous line of therapy. 
A.4 Statistical analysis 
Lifetable survival estimates were generated for the patient cohort by treatment regimen to extrapolate 
the survival estimates from the RCT using the SEER-Medicare data.  These survival estimates from 
SEER-Medicare for a population reflected as closely as possible to the RCT were blended (added, see 
Section 2.5) with the survival estimates from the RCT for the extrapolations. 
  
SEER-Medicare Flow Chart  
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